The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of oral COH29, a novel ribonucleotide reductase (RNR) inhibitor in adult patients (pts) with advanced solid tumors.
 
Joseph Chao
Consulting or Advisory Role - Bayer; Boston Biomedical; Five Prime Therapeutics; Lilly
Research Funding - Merck (Inst)
 
Timothy W. Synold
No Relationships to Disclose
 
Paul Henry Frankel
No Relationships to Disclose
 
Joanne E. Mortimer
Honoraria - Novartis (I)
Consulting or Advisory Role - Puma Biotechnology
Speakers' Bureau - Novartis (I)
Research Funding - Cephalon; Novartis
Other Relationship - Novo Nordisk
 
Vincent M. Chung
Consulting or Advisory Role - Celgene; Perthera
Speakers' Bureau - Celgene
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene
 
D. Lynne Smith
No Relationships to Disclose
 
Rajiv Nallu
No Relationships to Disclose
 
Raju K. Pillai
No Relationships to Disclose
 
James Simpson
No Relationships to Disclose
 
David Horne
Stock and Other Ownership Interests - Novonco Therapeutics
Patents, Royalties, Other Intellectual Property - City of Hope
 
Larry W. Kwak
Stock and Other Ownership Interests - Antigenics; XEME BioPharma
Consulting or Advisory Role - Celltrion; Sella Life Sciences; XEME BioPharma
 
Linda Malkas
No Relationships to Disclose